# ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome

> **NCT07531745** · PHASE1,PHASE2 · RECRUITING · sponsor: **Ionis Pharmaceuticals, Inc.** · enrollment: 32 (estimated)

## Conditions studied

- Dravet Syndrome

## Interventions

- **DRUG:** ION337

## Key facts

- **NCT ID:** NCT07531745
- **Lead sponsor:** Ionis Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2030-12
- **Final completion:** 2030-12
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07531745

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07531745, "ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT07531745. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*